肾移植受者基于证据的心血管-肾脏-代谢治疗
本综述汇总了肾移植受者(KTR)中新型心血管-肾脏-代谢药物的证据,提出肾素-血管紧张素-醛固酮系统抑制剂、他汀类、SGLT2抑制剂和GLP-1受体激动剂为改善心肾结局的四大支柱,并讨论药物相互作用与耐受性。
要点
- RAAS抑制剂仍是KTR药物治疗的基石。
- SGLT2抑制剂和GLP-1受体激动剂有系统综述和荟萃分析支持。
- 非甾体/甾体MRA和ARNI证据不足,不推荐常规使用。
核心结论
- 基于现有证据,RAAS抑制剂、他汀类、SGLT2抑制剂和GLP-1受体激动剂构成改善KTR下游心肾结局的四大支柱。
研究设计与样本
- 综述汇总了KTR中使用新型心血管-肾脏-代谢药物的当前证据,包括系统综述、荟萃分析和随机对照试验数据。
主要发现
- RAAS抑制剂继续作为KTR多种适应证的药物治疗基石。
- 系统综述和荟萃分析支持SGLT2抑制剂和GLP-1受体激动剂用于合并多种 comorbidity 的KTR。
- 非甾体/甾体盐皮质激素受体拮抗剂和血管紧张素受体-脑啡肽酶抑制剂的证据正在涌现,但不足以支持KTR常规临床使用。
- 随机对照试验数据提示他汀类对肾移植后代谢环境有影响。
临床怎么用
- KTR中应优先使用RAAS抑制剂、他汀类、SGLT2抑制剂和GLP-1受体激动剂以改善心肾结局。
- 使用上述药物时需注意与免疫抑制剂的药物相互作用及耐受性。
- 针对冠心病、心力衰竭和心房颤动的管理需考虑KTR的特殊性。
局限性
- 非甾体/甾体MRA和ARNI在KTR中的证据尚不充分。
- 该脆弱人群仍需专门以改善心肾复合结局为目标的随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pivotal clinical trials have heralded several new classes of pharmacologic agents focused on improving combined heart-kidney outcomes among patients with cardiovascular-kidney-metabolic syndrome. This review compiles the current evidence pertaining to the use of these novel, exciting classes of agents among kidney transplant recipients (KTRs). Treatment with renin-angiotensin-aldosterone system inhibitors continues to remain the backbone of pharmacologic management among KTRs for several indications. Data from systematic reviews and meta-analyses support the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists with several comorbidities. However, evidence for both nonsteroidal and steroidal mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors is emerging and not adequate to support routine clinical use in KTRs. Finally, data from randomized controlled trials on statins serve as a reminder of their impact in the metabolic milieu following kidney transplantation. Using the recently introduced paradigm of cardiovascular-kidney-metabolic syndrome, this review proposes that four pharmacologic agents constitute the key pillars for improving downstream heart-kidney outcomes on the basis of existing evidence: renin-angiotensin-aldosterone system inhibitors, statins, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists. Furthermore, this review highlights relevant practical drug interactions with immunosuppressants and considerations of tolerability of these agents among KTRs. Finally, this review discusses specific management considerations for coronary heart disease, heart failure, and atrial fibrillation with unique nuances applicable to KTRs. There remains a critical need for randomized trials in this vulnerable population focused on improvement in combined heart-kidney outcomes.
引用
- Shroff GR, Cheng X, Gharabagi A, et al. Evidence-Based Cardiovascular-Kidney-Metabolic Therapies in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2026. PMID: 42522128. doi:10.2215/CJN.0000001195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。